8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jan 26, 2012)

Filed January 26, 2012For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on January 26, 2012, to announce its financial results for the fourth quarter and full year of 2011. The filing primarily serves to furnish a press release detailing these results, which is incorporated by reference as Exhibit 99.1. Additionally, supplemental information available on the company's website, referenced as Exhibit 99.2, is also made part of the filing. Investors should note that this 8-K is a notification of the release of financial results and does not contain new operational or strategic disclosures beyond what is presented in the accompanying press release and supplemental data. To understand the company's performance and financial condition for the period, stakeholders would need to review these attached exhibits.

Key Highlights

  • 1Bristol-Myers Squibb announced its Q4 and full-year 2011 financial results on January 26, 2012.
  • 2The 8-K filing's primary purpose is to officially report the release of these financial results.
  • 3A press release detailing the financial results for the fourth quarter and twelve months of 2011 is attached as Exhibit 99.1.
  • 4Supplemental financial information, accessible via the company's website, is also incorporated by reference as Exhibit 99.2.
  • 5The filing itself does not contain extensive narrative or new business updates, but rather points to the detailed financial disclosures in the exhibits.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Bristol-Myers Squibb's financial results for the fourth quarter and the full year of 2011. It serves as a notification to investors and the market that these results have been released.

The detailed financial results are primarily found in the press release (Exhibit 99.1) attached to this 8-K filing. Additional supplemental financial information, not included in the press release, is also referenced as Exhibit 99.2 and can be found on Bristol-Myers Squibb's website (www.bms.com).

This specific 8-K filing is focused on the release of financial results. While the accompanying press release and supplemental information may contain some commentary on performance, the 8-K itself does not introduce significant new strategic information or operational updates beyond what is disclosed in those financial reporting documents.